Startup Funding Tracker
Home›People›Kelly Huang
Kelly Huang

Kelly Huang

President and chief executive officer at Elucid

ExecutiveDirector
LinkedInLeadership page on elucid.com
Updated Nov 4, 2026·Latest SEC filing Oct 27, 2026·Suggest an edit

About Kelly Huang

Kelly Huang is president and chief executive officer of Elucid, a Boston company that makes AI software to read plaque in heart and neck arteries on CT scans. Elucid named Huang CEO in July 2024. Elucid named Huang to its board in November 2023, when Huang was a senior advisor to Elevage Medical Technologies, which led Elucid's Series C round. Huang has also served on the boards of Sanova Dermatology and the Princeton Innovation Accelerator.

Earlier, Huang joined Cardea Bio as chief operating officer in 2021. Huang was chief operating officer of L-Nutra in 2020, then head of its nutri-therapeutic division until 2021. At Obalon Therapeutics, Huang was chief operating officer from 2017 and chief executive officer from January to May 2019. From 2015 to 2017, Huang was general manager of the Galderma aesthetics business at Nestle Skin Health. Huang also held senior roles at HealthTronics, Endo Pharmaceuticals and Johnson & Johnson, and holds a PhD in chemical engineering from Stanford University.

Experience

This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Kelly Huang in the role, so the role may have started earlier or lasted longer.

Elucid Bioimaging Inc. Current
President and Chief Executive Officer, director
2023 – Present · Boston, MA
Elucid makes AI software that measures plaque in heart and neck arteries from CT scans to help doctors choose treatment.
Cardea Bio
Chief Operating Officer
From 2021
L-Nutra
Head of the Nutri-Therapeutic Division (2020 – 2021)
Chief Operating Officer (2020)
2020 – 2021
Obalon Therapeutics
President and Chief Executive Officer (2019)
Chief Operating Officer (2017 – 2019)
2017 – 2019
Nestle Skin Health
General Manager, Galderma aesthetics business
2015 – 2017
Elevage Medical Technologies
Senior Advisor
HealthTronics
President, Urology Device and Services business
Endo Pharmaceuticals
Neutrogena Corporation
Vice President of Research and Development and corporate officer
Johnson & Johnson Development Corporation
Vice President
Sanova Dermatology
Board member
Princeton Innovation Accelerator
Board member

Key Colleagues at Startups

The people Kelly Huang works with at each company, as listed on that company's latest Form D.

Elucid Bioimaging Inc. · Form D/A, Oct 27, 2026
Blake Richards
Blake Richards
Chief Operating Officer
Scott Huennekens
Scott Huennekens
Chairman of the Board
ML
Michael Lesh
Director
RK
EM
Evan Melrose
Director
SF
RP
Rajesh Panda
Director

Kelly Huang in the News

Sources

  1. SECElucid Bioimaging Inc. Form D/A, filed Oct 27, 2026
  2. PressElucid names Kelly Huang as CEO (July 22, 2024)
  3. PressElucid Series C release naming him to the board (November 9, 2023)
  4. Company siteBiography on spindletophealth.com
  5. PressCardea Bio release naming him chief operating officer (June 22, 2021)
  6. SECObalon Therapeutics 10-K/A for 2019